Policy Pulse Live: Access to Amyloidosis Treatments

Cardiac Amyloidosis has been considered a rare disease and awareness of this condition has been low, and there are no guidelines established on the standard of care. Less than half of cardiologists have reported that they are familiar with the tools and tests used to confirm cardiac amyloidosis. Most people with cardiac amyloidosis either never receive a proper diagnosis or remain undiagnosed for many years until symptoms are severe and only after seeing numerous specialists. Amyloidosis often affects the heart, nervous system kidneys, liver, spleen, and digestive tract. Persons of African descent are at higher risk of carrying a genetic mutation associated (as much as 3-4%) with the type of amyloidosis that is damaging to the heart. This educational program aims to address this educational gap and to heighten awareness around the importance of early diagnosis.

The call to action is for health care providers and non-physicians to become informed and aware of cardiac amyloidosis and its symptoms, back efforts to educate healthcare providers on diagnostic techniques and symptoms awareness, and support funding for programs that reduce barriers to screening and provide coverage for diagnosis and treatment of cardiac amyloidosis.

Wednesday, December 11, 2019

6:30p – 7:00p | Registration
7:00p – 8:30p | Program

One Ocean Resort & Spa | Pristina Room
One Ocean Boulevard | Atlantic Beach, FL 32233

Keynote Speaker: Taimur Sher, MBBS, MD
Associate Professor of Medicine
Department of Hematology and Oncology
Mayo Clinic

Local Host: Gladys P. Velarde, MD, FACC, FAHA
Associate Professor of Medicine
Director Women’s Cardiovascular Health Program
Director Cardiovascular Fellowship Program
University of Florida College of Medicine-Jacksonville
Division of Cardiology